Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19948765 | 0.82 | ESR2 (0.55) | ESR2NR1H2ABHD6MKNK1ADORA1 | |
| SCHEMBL29446113 | 0.82 | ESR2 (0.55) | ESR2NR1H2ABHD6MKNK1ADORA1 | |
| SCHEMBL30260187 | 0.80 | ESR2 (0.60) | ESR2NR1H2ABHD6MKNK1ADORA1 | |
| SCHEMBL17583921 | 0.80 | ESR2 (0.60) | ESR2NR1H2ABHD6MKNK1ADORA1 | |
| SCHEMBL31447559 | 0.79 | NR1H2 (0.60) | ESR2NR1H2ABHD6MKNK1ADORA1 | |
| SCHEMBL17018770 | 0.79 | NR1H2 (0.60) | ESR2NR1H2ABHD6MKNK1ADORA1 | |
| SCHEMBL20704305 | 0.78 | ESR2 (0.63) | ESR2NR1H2ABHD6NPC1RAB9A | |
| SCHEMBL19358055 | 0.77 | HDAC1 (0.46) | ESR2NR1H2ABHD6MAPK1NPC1 | |
| SCHEMBL19642882 | 0.77 | ESR2 (0.55) | ESR2NR1H2ABHD6MKNK1ADORA1 | |
| SCHEMBL29405503 | 0.77 | ESR2 (0.55) | ESR2NR1H2ABHD6MKNK1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-30 | — | — | US | disclosed |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | US | disclosed |
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, NFKBIA, MAP3K15 | ESR2 3706/4885NR1H2 681/4885ABHD6 2289/4885 |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | ESR2 3961/4885NR1H2 1193/4885ABHD6 3078/4885 |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | ESR2 3706/4885NR1H2 681/4885ABHD6 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.